Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting now · Phase 2

Conditions studied: Non-Hodgkin's Lymphoma

In brief

The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL.

Key facts

Study ID

NCT04586478

Run by

Juventas Cell Therapy Ltd.

People needed

60

Starts

2020-10-26

Expected to finish

2025-09-30

Last updated by the study team

2025-02-07

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who are willing to sign the informed consent form;
• Aged 18-75 years, male or female;
• At screening, subjects complying with the following diagnostic and treatment requirements:
• Complying with CD19-positive NHL according to the WHO classification 2017, which are provided specifically as follows:
• Diffuse large B cell lymphoma (DLBCL), not otherwise specified (NOS);
• Primary mediastinal large B cell lymphoma (PMBCL);
• Transformed follicular lymphoma
• High grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high grade B cell lymphoma - not otherwise specified.
• Previously received≥2nd-line adequate therapy or autologous hematopoietic stem cell transplantation (ASCT), including:
• Received at least Rituximab or other CD20 targeted drugs containing (except CD20 negative tumors) chemotherapy and
• Received at least one chemotherapy regimen containing anthracycline;
• Definition of line: Stable disease (SD) after receiving a first-line adequate therapy or progressive disease (PD), and SD after a second-line therapy for at least 2 cycles or PD .
• In relapsed or refractory status at screening:
• Definition of relapse: Remission (including partial remission (PR) or complete remission (CR)) after treatment with at least the standard therapy regimen (it must contain Ribuximab), and then PD;
• Definition of refractoriness:
• Non-responsiveness to the last therapy: The best response by the last therapy is SD or PD; Relapse or progression after ASCT, including: Relapse (it must be proved by biopsy) or PD within 12 months after ASCT; if a rescue therapy is received, the patient is non-responsive (SD or PD) to the last therapy;
• For transformed follicular lymphoma (TFL), patients must be treated adequately against FL, and after transformation, must have received at least once the therapy against TFL, and become relapsed or refractory after the last therapy.
• Measurable imaging lesion at screening: Intranodal lesion must have a long diameter of more than 1.5 cm, and extranodal lesion must have a long diameter of more than 1.0 cm (per revised IWG Response Criteria 2014 in Lymphomas);
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
• Adequate bone marrow reserve, defined as:
• Absolute neutrophil count (ANC) > 1.0×109/L;
• Absolute lymphocyte count (ALC) ≥ 0.3×109/L;
• Platelet (PLT) ≥50×109/L;
• Proper organ function, complying with the following criteria (except hepatic dysfunction due to tumor cell infiltration): Aspartate aminotransferase (AST) ≤ 3 Upper Limit of Normal (ULN); Alanine aminotransferase (ALT) ≤ 3 ULN; Total serum bilirubin ≤ 2 ULN, unless there exists concurrent Gilbert syndrome; patients with Gilbert syndrome, with total serum bilirubin ≤ 3 ULN and direct bilirubin ≤ 1.5 ULN, may be included; Renal function: serum creatinine ≤ 1.5 ULN or creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula); Minimum pulmonary reserve, defined as Grade ≤ 1 dyspnea, and blood oxygen saturation > 91% at non-oxygen inhalation status; International normalized ratio (INR) ≤ 1.5 ULN and activated partial thromboplastin time (aPTT) ≤ 1.5 ULN.
• Vascular conditions for apheresis;

You may not qualify if…

• Patients with active central nervous system (CNS) lymphoma (a patient with CNS disease symptoms must receive lumbar puncture and MRI/CT to exclude CNS lymphoma).
• Patients with existing central nervous system disease or with a history of central nervous system disease, e.g., epileptic seizure, cerebral ischemia/hemorrhage, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellum disease, organic brain syndrome, mental disease, or any autoimmune disease involved with central nervous system.
• Patients receiving any of the following drugs or therapies within the specified period prior to apheresis:
• Alemtuzumab within 6 months prior to apheresis;
• Cladribine within 3 months prior to apheresis;
• Anti-CD20 monoclonal antibody within 7 d prior to apheresis;
• Venetoclax (BCL-2 inhibitor) within 4 d prior to apheresis;
• Idelalisib (PI3Kδ kinase inhibitor) within 2 d prior to apheresis;
• Lenalidomide within 1 d prior to apheresis;
• Lymphocytotoxic chemotherapy within 2 weeks prior to apheresis - use in more than 3 half-lives prior to apheresis is eligible;
• Non-lymphocytotoxic chemotherapy within 7 d prior to apheresis - use in more than 3 half-lives prior to apheresis is eligible;
• Radiotherapy within 6 weeks prior to apheresis, including big bone marrow area (e.g., sternum or pelvis) - progressive disease at radiotherapy site, or PET positive lesion at other non-radiotherapy site is eligible; if there is existing PET positive lesion in other non-radiotherapy sites, then it is allowable to conduct radiotherapy at a single lesion within 2 weeks prior to apheresis.
• Patients receiving chemotherapy within 2 weeks prior to CNCT19 Cell injection infusion, excluding the following conditions:
• Pretreatment chemotherapy as specified by the protocol;
• CNS lymphoma prophylaxis by intrathecal injection (it must be stopped within 1 week prior to infusion of CNCT19 Cell Injection).
• Discontinuation of a systematic therapeutic hormone within 72 h prior to infusion of CNCT19 Cell Injection; however, use of the hormone in the physiological surrogate amount is eligible (e.g., Prednisone in a dose of <10 mg/d or equivalent).
• Patients previously received CAR-T cell therapy.
• Patients who have previously received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
• Patients with known active or uncontrolled synstemic autoimmune disease and under treatment.
• Patients complying with any of hepatitis B surface antigen (HBsAg) and/or hepatitis B e antigen (HBeAg) positive, hepatitis B e antibody (HBe-Ab) and/or hepatitis B core antibody (HBc-Ab) positive and HBV-DNA copies being more than the lower limit of detection, hepatitis C antibody (HCV-Ab) positive, anti-treponemia pallidum antibody (TP-Ab) positive, EBV-DNA, and CMV-DNA copies being more than the lower limit of detection.
• Patients who received a major surgery within 4 weeks prior to screening, and are not eligible for enrollment as judged by the investigator.
• Patients with concurrent active malignancy; those with a history of malignancy, cured for≥2 years, are eligible.
• Patients complying any of the following conditions: Left ventricular ejection fraction (LVEF) ≤45% (ECHO); New York Heart Association (NYHA) Grade III or IV congestive heart failure; Uncontrolled hypertension (systolic blood pressures≥140mmHg and/or diastolic blood pressures ≥90 mmHg), pulmonary hypertension, or unstable angina pectoris; Myocardial infarction or bridging or stent procedure within 12 months prior to administration of the drug; Clinically significant valvular heart disease; Other heart diseases unsuitable for enrollment, as judged by the investigator.
• Patients with lymphoma involved with atrium or ventricle.
• Patients with clinical emergency (e.g., intestinal infarction or vascular compression) requiring treatment, due to existing lymphoma body obstruction or compression at screening.

Where it is running

• Beijing Boren Hospital — Beijing, Beijing Municipality, China (enrolling)
• Beijing Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)
• Peking University Third Hospital — Beijing, Beijing Municipality, China (enrolling)
• The First Affiliated Hospital of Chongqing Medical University — Chongqing, Chongqing Municipality, China (enrolling)
• Xinqiao Hospital of TMMU — Chongqing, Chongqing Municipality, China (enrolling)
• Guangdong Provincial Peoples' Hospital — Guangzhou, Guangdong, China (enrolling)
• SunYat-Sen University Cancer Center — Guangzhou, Guangdong, China (enrolling)
• Henan Cancer Hospital — Zhengzhou, Henan, China (enrolling)
• The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (enrolling)
• Tongji Hospital, Tongji Medical College of HUST — Wuhan, Hubei, China (enrolling)
• Qilu Hospital of Shandong University — Jinan, Shandong, China (enrolling)
• Ruijin Hospital, Shanghai Jiaotong University School of Medicine — Shanghai, Shanghai Municipality, China (enrolling)
• Tongji Hospital of Tongji University — Shanghai, Shanghai Municipality, China (enrolling)
• West China Hospital，Sichuan University — Chengdu, Sichuan, China (enrolling)
• Institute of Hematology & Blood Diseases Hospital — Tianjin, Tianjin Municipality, China (enrolling)
• Tianjin Medical University Cancer Institute & Hospital — Tianjin, Tianjin Municipality, China (enrolling)
• The First Affiliated Hospital, Zhejiang University school of Medicine — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.